Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
170 hedge funds and large institutions have $1.01B invested in Five Prime Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 69 increasing their positions, 40 reducing their positions, and 20 closing their positions.
155% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 20
73% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 40
21% more funds holding
Funds holding: 140 → 170 (+30)
9% more capital invested
Capital invested by funds: $932M → $1.01B (+$81.9M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
89% less call options, than puts
Call options by funds: $633K | Put options by funds: $5.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$25.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$20.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.4M |
| 5 |
O
OppenheimerFunds
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$44.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$23.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20.3M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$15.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$12.4M |
FPRX Hedge Fund Activity: Q2 2016 in Review
170 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2016, worth a combined $1.01B — up 8.8% from $932M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new FPRX positions and 20 closed out — a net gain of 31 holders — while 69 added to existing stakes and 40 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $25.2M. The largest seller was Versant Venture Management, exiting entirely with an estimated $44.4M sold.
- 170 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2016, up from 140 in Q1 2016.
- Funds reported $1.01B of Five Prime Therapeutics, Inc. stock for Q2 2016, up 8.8% quarter-over-quarter.
- 51 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2016 and 20 closed out, a net change of +31 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q2 2016 was Acadian Asset Management, an estimated $25.2M added.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2016 was Versant Venture Management, an estimated $44.4M sold.
Based on aggregated 13F filings for Q2 2016.